Strategic Approaches to Biomarker Testing in NSCLC: Optimal Timing
Experts reflect on the evolving landscape of biomarker testing in lung cancer, examining its crucial role in treatment decisions and advancements in perioperative and adjuvant therapies.
Read More
Optimizing the Selection of Novel Therapy for Patients With Advanced NSCLC
Closing out their panel on immunotherapy in non–small cell lung cancer, expert oncologists share key takeaways on the selection of novel therapy in this setting.
Read More
Advanced NSCLC: Interpreting Data From the POSEIDON Trial
A brief review of the POSEIDON trial, which analyzed durvalumab with or without tremelimumab in combination with chemotherapy in advanced NSCLC.
Read More
Role for IO Therapy in Advanced NSCLC With Concomitant KRAS and KEAP1/STK11 Mutations
Key opinion leaders in the field of non–small cell lung cancer management discuss the role of immunotherapy in patients with concomitant KRAS and KEAP1/STK11 mutations.
Read More
Combination Chemo + IO Therapy in Advanced Non–Small Cell Lung Cancer
A comprehensive discussion on combination chemotherapy + immunotherapy regimens available to patients with advanced non–small cell lung cancer.
Read More
Selecting Therapy for Advanced NSCLC Based on PD-L1 and NGS Testing
Shared insight on the value that molecular testing and PD-L1 testing, respectively, have on determining optimal therapy for patients with advanced non–small cell lung cancer.
Read More
Factors in Selecting IO Therapy for Patients With Advanced NSCLC
Switching their focus to advanced non–small cell lung cancer, panelists identify parameters that may influence the use of immune checkpoint inhibitors in this setting.
Read More
Considerations for Incorporating Perioperative Treatment in Resectable NSCLC
Before closing out their review of resectable NSCLC treatment strategies, key opinion leaders consider nuances in utilizing perioperative therapy in the current paradigm.
Read More
Adjuvant Treatment Strategies in Resectable Non–Small Cell Lung Cancer
Switching their focus to the adjuvant setting of resectable NSCLC, expert panelists identify treatment options in this setting and review the clinical data behind them.
Read More
What is the Role of Molecular Testing in Resectable Non–Small Cell Lung Cancer?
Shared insight from key opinion leaders on the value of molecular testing in patients with resectable non–small cell lung cancer and how it can be applied.
Read More
Practical Advice on the Evolving Management of CSCC
Closing out their discussion on the management of cutaneous squamous cell carcinoma, expert panelists share clinical pearls and excitement for the future.
Read More
Resectable Non–Small Cell Lung Cancer: Neoadjuvant Treatment Strategies
Focused discussion on the selection of neoadjuvant therapy in patients with resectable NSCLC in light of recent clinical trials.
Read More
Key Decisionmaking Factors in Resectable Non–Small Cell Lung Cancer
Expert oncologists reflect on key factors that aid in the selection of therapy for patients diagnosed with resectable non–small cell lung cancer (NSCLC).
Read More
CSCC: Escalating Therapy for High-risk Patients
Dr Vishal Patel shares a surgeon’s perspective on MDC, followed by a discussion on how intensifying treatment after surgery may improve outcomes for higher-risk patients with CSCC.
Read More
Best Practices in Multidisciplinary Care for CSCC
Experts in the field of CSCC revisit the concept of multidisciplinary care and consider best communication strategies.
Read More
Other Emerging Treatment Modalities in Cutaneous Squamous Cell Carcinoma
Shared insight on novel treatment modalities in the setting of cutaneous squamous cell carcinoma and how they may be triaged moving forward.
Read More
CSCC: Translating Cemiplimab Data Into Practice
Following their review of recent clinical data, expert panelists consider how neoadjuvant cemiplimab will fit into the real-world treatment paradigm of resectable CSCC, including the possibility of delaying or avoiding surgery in patients who have an adequate response to cemiplimab.
Read More
Neoadjuvant IO Therapy Trials in Resectable CSCC and Cemiplimab Data Updates
A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors—pembrolizumab, atezolizumab, and cemiplimab—in CSCC, followed by a focused discussion of recent cemiplimab trial data.
Read More
Lessons Learned in Other Cancers and Suggested Endpoints in Future Trials
Key opinion leaders take time to review how immune checkpoint inhibitors have transformed outcomes in rectal cancer and non-cutaneous squamous cell cancers and consider how to better structure clinical trial endpoints in CSCC.
Read More
Clinical Experience With Neoadjuvant IO Therapy in Melanoma
Shared insight on the use of immune checkpoint inhibitors in other patient populations within the skin cancer paradigm, and how lessons may be applied to patients with CSCC.
Read More
Evolving Treatment Paradigm of Resectable CSCC
Expert panelists consider the broader evolution of therapy in resectable stage II-IV cutaneous squamous cell carcinoma.
Read More
Real World Experience With Resectable Cutaneous Squamous Cell Carcinoma
Expert perspectives on real-world, in-practice identification and management of patients with resectable CSCC.
Read More
Staging and Risk Stratification’s Impact on Treatment Approach in CSCC
Panelists round out their review of staging and risk stratification in CSCC by considering how each affects the selection of optimal surgical strategies.
Read More
Defining Resectability in CSCC
Following their discussions on staging and risk stratification in CSCC, key opinion leaders work to define resectability in cutaneous squamous cell carcinoma.
Read More
Optimal Risk Stratification in Patients With Cutaneous Squamous Cell Carcinoma
Expert panelists share their perspectives on best strategies to risk stratify patients diagnosed with cutaneous squamous cell carcinoma.
Read More
Available Staging Systems for Cutaneous Squamous Cell Carcinoma
A review of current staging systems used to categorize CSCC, particularly those from the American Joint Committee on Cancer and Brigham and Women's Hospital.
Read More
Cutaneous Squamous Cell Carcinoma: Incidence and Risk Factors
Opening their discussion on resectable cutaneous squamous cell carcinoma (CSCC), expert panelists elucidate its current incidence and known risk factors.
Read More
Experts on the Use of ADCs in HER2-Mutated NSCLC Treatment
December 23rd 2022Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss the use of antibody-drug conjugates (ADCs) in HER2-mutated non–small cell lung cancer.
Read More